<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04599556</url>
  </required_header>
  <id_info>
    <org_study_id>CD7-001</org_study_id>
    <nct_id>NCT04599556</nct_id>
  </id_info>
  <brief_title>Clinical Trial for the Safety and Efficacy of Anti-CD7 CAR-T Cell Therapy for Patients With Relapsed or Refractory CD7 Positive Hematological Malignancy</brief_title>
  <official_title>Clinical Trial for the Safety and Efficacy of Anti-CD7 Chimeric Antigen Receptor Cell Therapy for Patients With Relapsed or Refractory CD7 Positive Hematological Malignancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Yake Biotechnology Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Zhejiang University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, open-label, single-center clinical trial. This study will evaluate the&#xD;
      safety and efficacy of anti-CD7 CAR-T cells in the treatment of relapsed or refractory CD7&#xD;
      positive T-ALL, T-NHL and AML. The primary endpoints are dose limiting toxicity (DLT) and the&#xD;
      incidence of treatment emergent adverse event (TEAE).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicity</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment Emergent Adverse Event</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>CD7+ Acute Leukemia</condition>
  <condition>CD7+ Lymphoma</condition>
  <arm_group>
    <arm_group_label>T-ALL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>T-NHL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AML</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-CD7 CAR-T</intervention_name>
    <description>Lymphodepleting chemotherapy followed by anti-CD7 CAR-T infusion</description>
    <arm_group_label>AML</arm_group_label>
    <arm_group_label>T-ALL</arm_group_label>
    <arm_group_label>T-NHL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Total bilirubin ≤ 51 μmol / L, ALT and AST ≤ 3 times of the upper limit of normal&#xD;
             value, serum creatinine ≤ 176.8 μmol / L;&#xD;
&#xD;
          2. Echocardiography shows left ventricular ejection fraction (LVEF) ≥ 50%;&#xD;
&#xD;
          3. There is no active pulmonary infection, and the oxygen saturation during air&#xD;
             inhalation is more than 92%;&#xD;
&#xD;
          4. The estimated survival time is more than 3 months;&#xD;
&#xD;
          5. ECOG score was 0-2;&#xD;
&#xD;
          6. The patients or their legal guardians voluntarily participated in the trial and signed&#xD;
             the informed consent.&#xD;
&#xD;
        For T-ALL:&#xD;
&#xD;
          1. Patients is histologically diagnosed with CD7 Positive T-ALL according to the Clinical&#xD;
             Practice Guidelines for Acute Lymphoblastic Leukemia (ALL) (2020. V1) by National&#xD;
             Comprehensive Cancer Network (NCCN).&#xD;
&#xD;
          2. The diagnosis is consistent with r/r CD7 + T-ALL, and includes any of the following&#xD;
             conditions:&#xD;
&#xD;
               1. No CR was obtained by standard chemotherapy;&#xD;
&#xD;
               2. The first induction was CR, but the duration of CR was less than 12 months;&#xD;
&#xD;
               3. No CR was obtained after the first or multiple remedial treatment;&#xD;
&#xD;
               4. Relapse twice or more;&#xD;
&#xD;
          3. The number of blast cells in bone marrow was more than 5% (morphology) and / or &gt; 1%&#xD;
             (flow cytometry).&#xD;
&#xD;
        For T-NHL:&#xD;
&#xD;
          1. Patients is histologically diagnosed with CD7 Positive T-NHL according to The 2016&#xD;
             revision of the World Health Organization classification of lymphoid neoplasms.&#xD;
&#xD;
          2. r/r T-NHL, and includes any of the following conditions:&#xD;
&#xD;
               1. No response or relapse after second or more lines of chemotherapy;&#xD;
&#xD;
               2. Primary refractory ot chemotherapy;&#xD;
&#xD;
               3. Relapse after autologous stem cell transplantation;&#xD;
&#xD;
          3. According to the Lugano 2014 criteria, there is at least one evaluable tumor lesion.&#xD;
&#xD;
        For AML:&#xD;
&#xD;
          1. Patients is histologically diagnosed with CD7 Positive AML according to the Clinical&#xD;
             Practice Guidelines for Acute Myeloid Leukemia (AML) (2020. V3) by National&#xD;
             Comprehensive Cancer Network (NCCN).&#xD;
&#xD;
          2. The diagnosis is consistent with r/r CD7 + AML, and includes any of the following&#xD;
             conditions:&#xD;
&#xD;
               1. No CR was obtained by standard chemotherapy;&#xD;
&#xD;
               2. The first induction was CR, but the duration of CR was less than 12 months;&#xD;
&#xD;
               3. No CR was obtained after the first or multiple remedial treatment;&#xD;
&#xD;
               4. Relapse twice or more;&#xD;
&#xD;
          3. The number of blast cells in bone marrow was more than 5% (morphology) and / or &gt; 1%&#xD;
             (flow cytometry).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with history of epilepsy or other central nervous system diseases;&#xD;
&#xD;
          2. Patients with prolonged QT or severe heart disease;&#xD;
&#xD;
          3. Pregnant or lactating women (the safety of this therapy for unborn children is&#xD;
             unknown);&#xD;
&#xD;
          4. The patients with uncontrolled active infection;&#xD;
&#xD;
          5. Active hepatitis B or hepatitis C virus infection;&#xD;
&#xD;
          6. Previous application of gene therapy;&#xD;
&#xD;
          7. The proiferation rate is less than 5 times response to CD3/CD28 co-stimulation signal;&#xD;
&#xD;
          8. Serum creatinine &gt; 2.5mg/dl or ALT / AST &gt; 3 times ULN or bilirubin &gt; 2.0mg/dl;&#xD;
&#xD;
          9. Those who suffer from other uncontrolled diseases are not suitable to join the study;&#xD;
&#xD;
         10. HIV infection;&#xD;
&#xD;
         11. Any situation that the researchers believe may increase the risk of patients or&#xD;
             interfere with the test results.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yongxian Hu</last_name>
    <phone>+86-0571-87236476</phone>
    <email>huyongxian2000@aliyun.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital，College of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>He Huang, PhD</last_name>
      <phone>86-13605714822</phone>
      <email>hehuangyu@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 21, 2020</study_first_submitted>
  <study_first_submitted_qc>October 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2020</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhejiang University</investigator_affiliation>
    <investigator_full_name>He Huang</investigator_full_name>
    <investigator_title>The President of The First Affiliated Hospital, College of Medicine, Zhejiang University</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

